Cancer phase I clinical trials: efficient dose escalation with overdose control

James S. Babb, André Rogatko, Shelemyahu Zacks

Type: Article

Publication Date: 1998-05-30

Citations: 611

DOI: https://doi.org/10.1002/(sici)1097-0258(19980530)17:10<1103::aid-sim793>3.0.co;2-9

View Publication

Locations

PubMed - View
Statistics in Medicine - View

Similar Works

Action	Title	Year	Authors
+ PDF Chat	Adaptive Dose-Finding Studies: A Review of Model-Guided Phase I Clinical Trials	2014	Alexia Iasonos John O’Quigley
+	Hybrid continuous reassessment method with overdose control for safer dose escalation	2023	Debopriya Ghosh Hong Xie Liangcai Zhang Fei Chen Surya Mohanty Xiang Li
+ PDF Chat	A Brief Overview of Adaptive Designs for Phase I Cancer Trials	2022	Anshul Saxena Muni Rubens Venkataraghavan Ramamoorthy Zhenwei Zhang Md Ashfaq Ahmed Peter McGranaghan Sankalp Das Emir Veledar
+	Continual Reassessment Method for a First-in-Human Trial: From Design to Trial Implementation	2014	Inna Perevozskaya Lixin Han Kristen J. Pierce
+ PDF Chat	Improving safety of the continual reassessment method via a modified allocation rule	2019	Pavel Mozgunov Thomas Jaki
+	Adaptive continual reassessment method: A maximum tolerated dose estimation method in phase I clinical trial	2024	E.J. Park Eun Jeong Min
+	Practical modifications of the continual reassessment method for phase i cancer clinical trials	1994	Douglas E. Faries
+	Accuracy, Safety, and Reliability of Novel Phase I Trial Designs	2018	Heng Zhou Ying Yuan Lei Nie
+ PDF Chat	Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method	2019	Lingyun Ji Juan Pablo Lewinger Mark Krailo Susan Groshen David V. Conti Shahab Asgharzadeh Richard Sposto
+	Adaptive Search of an MTD in Cancer Phase I Clinical Trials	2008	Shelemyahu Zacks
+ PDF Chat	A Generalized Continual Reassessment Method for Two-Agent Phase I Trials	2013	Thomas M. Braun Nan Jia
+ PDF Chat	A Bayesian adaptive design for cancer phase I trials using a flexible range of doses	2017	Mourad Tighiouart Galen Cook‐Wiens André Rogatko
+	Data from Accuracy, Safety, and Reliability of Novel Phase I Trial Designs	2023	Heng Zhou Ying Yuan Lei Nie
+	Data from Accuracy, Safety, and Reliability of Novel Phase I Trial Designs	2023	Heng Zhou Ying Yuan Lei Nie
+ PDF Chat	Incorporating a Patient Dichotomous Characteristic in Cancer Phase I Clinical Trials Using Escalation with Overdose Control	2012	Mourad Tighiouart Galen Cook‐Wiens André Rogatko
+ PDF Chat	GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials	2020	Derek Dinart Julien Fraisse Diégo Tosi Audrey Mauguen Célia Touraine Sophie Gourgou Marie‐Cécile Le Deley C. Bellera Caroline Mollévi
+	Envelope Simulation: A New Adaptive Method for Dose Optimization	2020	Steven Piantadosi Guohai Zhou
+ PDF Chat	Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials	2015	Zhengjia Chen Ying Yuan Li Zheng Michael Kutner Taofeek K. Owonikoko Walter J. Curran Fadlo R. Khuri Jeanne Kowalski
+ PDF Chat	Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials	2010	Mourad Tighiouart André Rogatko
+ PDF Chat	Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding	2015	André Rogatko Galen Cook‐Wiens Mourad Tighiouart Steven Piantadosi

Works That Cite This (476)

Action	Title	Year	Authors
+	Causal and Design Issues in Clinical Trials	2011	Rongmei Zhang
+ PDF Chat	Incorporating a Patient Dichotomous Characteristic in Cancer Phase I Clinical Trials Using Escalation with Overdose Control	2012	Mourad Tighiouart Galen Cook‐Wiens André Rogatko
+	Designing Clinical Trials for Dystonia	2013	Wendy R. Galpern Christopher S. Coffey Alberto Albanese Ken Cheung Cynthia Comella Dixie Ecklund Stanley Fahn Joseph Jankovic Karl Kieburtz Anthony E. Lang
+ PDF Chat	TEAMS: Toxicity- and Efficacy-Based Dose-Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology	2015	Wentian Guo Yang Ni Yuan Ji
+ PDF Chat	A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs	2014	Codruța Chiuzan Elizabeth Garrett‐Mayer Sharon D. Yeatts
+ PDF Chat	A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison	2024	Yong Zang Peter F. Thall Ying Yuan
+	Phase I Clinical Trial Design in Cancer Drug Development	2000	Elizabeth A. Eisenhauer Peter J. O’Dwyer Michaele C. Christian Jeffrey S. Humphrey
+ PDF Chat	Random-effects meta-analysis of Phase I dose-finding studies using stochastic process priors	2021	Moreno Ursino Christian Röver Sarah Zohar Tim Friede
+	A Bayesian zero-inflated binomial regression and its application in dose-finding study	2019	Puntipa Wanitjirattikal Chenyang Shi
+	A Likelihood Perspective on Dose‐Finding Study Designs in Oncology	2024	Zhiwei Zhang

Works Cited by This (0)

Action	Title	Year	Authors